A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NBI-1065845 AS ADJUNCTIVE TREATMENT IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

Registry ID

NBI-1065845-MDD3026

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NEUROCRINE BIOSCIENCES INC

Start date

2026-02-02

Last update

2025-06-04

Conditions

• MAJOR DEPRESSIVE DISORDER

Related clinical trials

• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ADJUNCTIVE TREATMENT WITH BRENIPATIDE IN DELAYING TIME TO RELAPSE COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER (RENEWMDD-1)
• PSILOCYBIN-ASSISTED PSYCHOTHERAPY FOR MAJOR DEPRESSIVE DISORDER IN WOMEN WITH A HISTORY OF CHILDHOOD MALTREATMENT: A PILOT TRIAL
• 18F]BCPP-EF PET IMAGING OF MITOCHONDRIAL COMPLEX I IN MAJOR DEPRESSIVE DISORDER, TREATMENT-RESISTANT MAJOR DEPRESSIVE DISORDER, AND LONG COVID (PASC)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE MAINTENANCE OF EFFECT OF NBI-1065845 AS AN ADJUNCTIVE TREATMENT IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
• PSILOCYBIN-ASSISTED THERAPY FOR COMORBID MAJOR DEPRESSIVE DISORDER AND ALCOHOL USE DISORDER: A PILOT RANDOMIZED CLINICAL TRIAL
• UNDERSTANDING AND TREATING SUICIDAL IDEATION WITH KETAMINE: A DIFFUSION MAGNETIC RESONANCE IMAGING STUDY

View on source registry